This is a type of cancer that starts in mast cells, another type of white blood cell. It's a form of systemic mastocytosis, meaning the mast cells are found throughout the body, not just in the blood. It's a serious condition that can affect many parts of the body and often leads to a short lifespan.
Every report comes from a Lived member, sent anonymously.
Have you tried Ayvakit (Avapritinib) for Mast-Cell Leukemia?
Mast-cell leukemia is a very rare and aggressive blood cancer. It is the most serious form of systemic mastocytosis, a group of diseases in which abnormal mast cells build up in the bone marrow and other organs. Mast cells normally help drive allergic and immune responses by releasing chemicals such as histamine. In this disease, they make up more than 20% of the cells in a bone marrow sample. As these cells crowd out healthy blood cells and invade the liver, spleen, bones and gut, people may have fatigue, weight loss, bone pain and digestive problems. Their chemicals can also cause flushing, itching and sudden drops in blood pressure. Some people have a slower, chronic form without organ damage, but most have an acute form that progresses quickly.
Most cases are linked to an acquired change in the KIT gene, which controls mast cell growth. About nine in ten people with mast-cell leukemia have a KIT change at one particular spot. These changes develop in the bone marrow during life and are not inherited. The disease usually appears in adults between 40 and 60. It can arise on its own or develop from an earlier, milder form of systemic mastocytosis.
A bone marrow biopsy is the key test. A specialist counts the mast cells and checks whether they look abnormal. Blood tests include a blood count, a blood smear to look for mast cells in circulation, and serum tryptase, a mast cell enzyme that is usually very high in this disease. Genetic testing for KIT and other mutations helps guide treatment. Other blood tests and scans show which organs are affected. Testing also checks for a second blood cancer, which is present in about a third of people with mast-cell leukemia.
Standard leukemia chemotherapy works poorly against this disease, so treatment centers on targeted drugs that block the overactive KIT protein. Midostaurin (Rydapt) and avapritinib (Ayvakit) are oral kinase inhibitors approved for mast-cell leukemia. They can reduce the abnormal mast cells and improve organ function, although responses are often partial or temporary. Avapritinib is not recommended when platelet counts are very low. For younger, fit people with a suitable donor, an allogeneic stem cell transplant (replacing the bone marrow with a donor's) offers the best chance of long-term control, but carries serious risks such as graft-versus-host disease and infection. Supportive care includes antihistamines to calm mast cell reactions, transfusions and bone-strengthening medicine. Clinical trials of newer drugs are an important option.
Mast-cell leukemia has a poor outlook. Median survival has been around a year and a half, and much shorter in the acute form with organ damage. Targeted drugs have improved survival compared with older treatments, and a transplant can lead to lasting remission for some people. Care usually happens at a center with mastocytosis or leukemia expertise. Treatment involves frequent blood tests, bone marrow checks and dose adjustments. Early conversations about goals and palliative support, which focuses on comfort and quality of life, can help with planning.
See a hematologist promptly about lasting flushing, unexplained weight loss, bone pain or abnormal blood counts, especially with a known mastocytosis diagnosis. Call your care team right away about a fever or unusual bleeding or bruising, since low blood counts make infections and bleeding dangerous. Fainting, trouble breathing or throat swelling during a reaction is an emergency: use epinephrine if prescribed and call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mast-Cell Leukemia is like, what's helped you, or ask the community a question.